Zynex Stock Forecast, Price & News

-0.39 (-2.54 %)
(As of 06/16/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume3,016 shs
Average Volume478,533 shs
Market Capitalization$521.66 million
P/E Ratio93.57
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ZYXI News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynex and its competitors with MarketBeat's FREE daily newsletter.

Zynex logo

About Zynex

Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES) device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. The company also supplies electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products; and distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers CM-1500, a blood volume monitor device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.69 out of 5 stars

Medical Sector

332nd out of 2,100 stocks

Electromedical Equipment Industry

8th out of 61 stocks

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Zynex (NASDAQ:ZYXI) Frequently Asked Questions

Is Zynex a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Zynex stock.
View analyst ratings for Zynex
or view top-rated stocks.

What stocks does MarketBeat like better than Zynex?

Wall Street analysts have given Zynex a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zynex wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Zynex's next earnings date?

Zynex is scheduled to release its next quarterly earnings announcement on Monday, July 26th 2021.
View our earnings forecast for Zynex

How were Zynex's earnings last quarter?

Zynex, Inc. (NASDAQ:ZYXI) issued its quarterly earnings results on Thursday, April, 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The firm earned $24.13 million during the quarter, compared to analysts' expectations of $23.63 million. Zynex had a net margin of 6.10% and a trailing twelve-month return on equity of 11.19%.
View Zynex's earnings history

How has Zynex's stock been impacted by Coronavirus (COVID-19)?

Zynex's stock was trading at $11.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZYXI shares have increased by 35.7% and is now trading at $15.05.
View which stocks have been most impacted by COVID-19

What guidance has Zynex issued on next quarter's earnings?

Zynex issued an update on its second quarter 2021 earnings guidance on Tuesday, May, 11th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $31 million-$32.50 million, compared to the consensus revenue estimate of $31.43 million.

What price target have analysts set for ZYXI?

4 analysts have issued 12-month price objectives for Zynex's stock. Their forecasts range from $19.00 to $25.00. On average, they expect Zynex's share price to reach $21.63 in the next twelve months. This suggests a possible upside of 43.7% from the stock's current price.
View analysts' price targets for Zynex
or view top-rated stocks among Wall Street analysts.

Who are Zynex's key executives?

Zynex's management team includes the following people:
  • Mr. Thomas Sandgaard, Founder, Pres, CEO & Chairman (Age 62, Pay $500.95k)
  • Mr. Daniel J. Moorhead, Chief Financial Officer (Age 49, Pay $350.98k)
  • Ms. Anna Lucsok, Chief Operating Officer (Age 35, Pay $170.89k)
  • Dr. Raelynn Maloney Ph.D., Director of Communications & Organizational Devel.
  • Ms. Chelle Van Burkleo, VP of Sales
  • Mr. Dave Anttila, Director of HR
  • Mr. Neil Friery, Pres & COO of Zynex Monitoring Solutions, Inc.
  • Mr. Joachim Sandgaard, Information Systems Mang.

What is Thomas Sandgaard's approval rating as Zynex's CEO?

81 employees have rated Zynex CEO Thomas Sandgaard on Thomas Sandgaard has an approval rating of 87% among Zynex's employees.

Who are some of Zynex's key competitors?

What is Zynex's stock symbol?

Zynex trades on the NASDAQ under the ticker symbol "ZYXI."

Who are Zynex's major shareholders?

Zynex's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.86%), Oak Ridge Investments LLC (5.35%), Punch & Associates Investment Management Inc. (1.38%), Geode Capital Management LLC (0.93%), Millennium Management LLC (0.86%) and Northern Trust Corp (0.70%). Company insiders that own Zynex stock include Daniel J Moorhead and Thomas Sandgaard.
View institutional ownership trends for Zynex

Which institutional investors are selling Zynex stock?

ZYXI stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Goldman Sachs Group Inc., Capital Impact Advisors LLC, Russell Investments Group Ltd., UBS Group AG, Massachusetts Financial Services Co. MA, Algert Global LLC, and Guggenheim Capital LLC. Company insiders that have sold Zynex company stock in the last year include Daniel J Moorhead, and Thomas Sandgaard.
View insider buying and selling activity for Zynex
or view top insider-selling stocks.

Which institutional investors are buying Zynex stock?

ZYXI stock was purchased by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC, Tygh Capital Management Inc., BlackRock Inc., Janney Montgomery Scott LLC, Janus Henderson Group PLC, Punch & Associates Investment Management Inc., Bridge City Capital LLC, and Millennium Management LLC.
View insider buying and selling activity for Zynex
or or view top insider-buying stocks.

How do I buy shares of Zynex?

Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zynex's stock price today?

One share of ZYXI stock can currently be purchased for approximately $15.05.

How much money does Zynex make?

Zynex has a market capitalization of $524.45 million and generates $80.12 million in revenue each year. The company earns $9.07 million in net income (profit) each year or $0.26 on an earnings per share basis.

How many employees does Zynex have?

Zynex employs 768 workers across the globe.

What is Zynex's official website?

The official website for Zynex is

Where are Zynex's headquarters?

Zynex is headquartered at 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112.

How can I contact Zynex?

Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303 703 4906 or via email at [email protected]

This page was last updated on 6/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.